MedTrace Logo

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

NCT01215123 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2016-02-22

Study results available
· View outcomes & findings →

Summary

This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.

Conditions

Interventions

DRUG

Bevacizumab

Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215123 on ClinicalTrials.gov